Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Rapid growth of pharmaceutical equipment, exploration and innovation of medical services, Fosun Pharma’s deduction of non-net profit increased by 26.8%
Category:
Trade info
Author: Fosun Pharma
Source:
Add time:2016-08-24 08:46
Note: The title and the figure above "deduct non-net profit" refers to the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses
On August 24, 2016, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharmaceutical”, stock code: 600196.SH, 02196.HK), a leading medical and healthcare industry group in China, announced 2016 Interim results.
In the first half of 2016, Fosun Pharma achieved operating income of RMB 6,937,091,200, an increase of 17.15% over the same period in 2015. After excluding the impact of the sale of Handan Pharmaceuticals, operating income increased by 18.79% compared with the same caliber in 2015. Among them: the pharmaceutical manufacturing and research and development business achieved operating income of RMB 4,848,716,400, an increase of 17.67% over the same period in 2015; after excluding the impact of the sale of Handan Pharmaceutical, operating income increased by 20.04% over the same caliber in 2015. The medical service business achieved operating income of RMB 753,117,500, an increase of 11.67% over the same period in 2015. In the first half of 2016, Fosun Pharma realized a net profit attributable to shareholders of listed companies deducting non-recurring gains and losses of RMB 1,118,942,800, an increase of 26.80% over the same period in 2015.
Chen Qiyu, Chairman of Fosun Pharma, said that in the first half of 2016, under the severe situation of global and Chinese economies still full of challenges and uncertainties, the reform of the national medical system continued to deepen, and the growth rate of the pharmaceutical industry continued to operate at a low level. Service development ushered in policy opportunities. Fosun Pharma adheres to the business philosophy of “continuous innovation and enjoyment of health”, focusing on the core business of pharmaceutical health, insisting on product innovation and management improvement, actively promoting endogenous growth, extensional expansion, and integrated development, and the main business continues Maintain balanced growth.
Continue to strengthen R&D investment, monoclonal antibody research and development have achieved fruitful results
Fosun Pharma has long focused on innovative research and development. In the first half of 2016, Fosun Pharma’s R&D investment (including capitalization) totaled RMB 488,649,200, an increase of 37.06% over the same period in 2015. Among them, the research and development expenses of the pharmaceutical manufacturing and research and development segment are RMB 242,455,000, accounting for 5% of the business income of the pharmaceutical manufacturing and research and development segment.
As of the end of the reporting period, Fosun Pharma is developing 172 new drugs, generic drugs, and biosimilar drugs and vaccines. During the reporting period, a total of 22 products received clinical approvals. Among them, the 1.1 category innovative drug PA-824 and tablets have been submitted to the State Food and Drug Administration for clinical applications; the development of monoclonal antibodies has been accelerated, recombinant human mouse chimeric anti-CD20 monoclonal antibody injection, recombinant anti-HER2 human source for injection Monoclonal antibody, recombinant anti-TNFα fully human monoclonal antibody injection, recombinant anti-VEGF humanized monoclonal antibody injection, and HLX07 (anti-EGFR humanized monoclonal antibody) Injection are in or approved to enter the clinical research stage, including: recombinant Human-mouse chimeric anti-CD20 monoclonal antibody injection has entered clinical phase III, recombinant anti-HER2 humanized monoclonal antibody for injection has been approved for clinical entry, and HLX07 (anti-EGFR humanized monoclonal antibody) Injection plans to carry out phase I clinical trials in Taiwan. During the reporting period, there were 37 patent applications in the pharmaceutical manufacturing and R&D sector, including 13 US patents and 2 PCT applications; 13 patents were granted, all of which are invention patents.
2
Fosun Pharmaceutical's pharmaceutical manufacturing and R&D business continued to maintain steady growth, and the professional management team was further strengthened. While continuously strengthening the innovation system, Fosun Pharma attaches great importance to the integration and construction of the product marketing system. In the first half of 2016, the sales of major core products in the treatment of cardiovascular system, anti-infection, central nervous system and other diseases maintained rapid growth. Among the new and inferior products, Udier (prostadilgan) in the treatment of cardiovascular diseases Milk) and Ulitre (febuxostat tablets) in the field of metabolic system therapy continued to maintain rapid growth, with a year-on-year increase of more than 100%. In 2015, the sales of 19 single preparations and series with sales of over 100 million yuan in the reporting period were relatively high. An increase of 26.45% in the same period in 2015.
In addition, after more than ten years of development, Sinopharm, in which Fosun Pharma’s equity investment, has become China’s largest distributor of pharmaceuticals and healthcare products and a leading supply chain service provider, it owns and operates China’s largest pharmaceutical distributor and Distribution network. At present, Sinopharm’s distribution network has covered 31 provinces, autonomous regions, and municipalities in China; its direct customers have reached 13,841 (only refers to tiered hospitals, including 1,880 of the largest and highest level tertiary hospitals); the retail pharmacy network has further expanded As of the end of the reporting period, its subsidiary Guoda Pharmacy has 3,268 retail pharmacies. Fosun Pharma maintains strategic cooperation with Sinopharm, and through cooperation with Sinopharm, it can give full play to the synergy between the two parties.
3
In the first half of 2016, the medical service business of Fosun Pharma Holdings achieved a total revenue of RMB 753,117,500, an increase of 11.67% over the same period in 2015; achieved segment performance of RMB 132,599,800, an increase of 14.06% over the same period in 2015; Segment profit was RMB 111,945,600, an increase of 66.64% over the same period in 2015. As of the end of the reporting period, there were 3,018 approved beds in Chancheng Hospital, Jimin Hospital, Guangji Hospital, Zhongwu Hospital and Wenzhou Geriatric Hospital controlled by the company.
Fosun Pharma continues to strengthen the strategic layout of the medical service business that has basically formed high-end medical care in developed coastal cities, specialists in second and third tier cities, and general hospitals, to build regional medical centers and a large health industry chain, and seek cooperation with local large-scale medical services. The cooperation model of state-owned enterprises, public hospitals and university hospitals accelerates the development of Internet medical services, and continues to increase business scale and profitability. In the first half of the year, Fosun Pharma started to participate in the "Qingdao Shanda Qilu Hospital Phase II Project" and the medical industry reorganization of related medical institutions that originally belonged to the Xukuang Group. The invested Wenzhou Geriatrics Hospital opened and started operating blood through Hunan Jingren Dialysis chain business.
In addition, Fosun Pharma continues to actively support and promote the development and deployment of the leading high-end medical service brand “United Family” hospitals and clinics under U.S.-China Mutual Benefit. In the first half of 2016, "United Family" Hospital continued to maintain its brand appeal and leading position in the high-end medical field in core cities such as Beijing, Tianjin, and Shanghai. Guangzhou United Family Hospital is also stepping up its construction.
4
Fosun Pharma continues to promote its own business development in the fields of medical diagnosis and medical devices. Among them, the dental digital product line has become a new growth point for Fosun Pharma’s medical device business. In the first half of 2016, it achieved a growth of 175% over the same period in 2015; Da Vinci surgical robots operated approximately 8,000 units in mainland China and Hong Kong. In the same period of 2015, an increase of approximately 49%; Alma Lasers continued to accelerate the development of the global market and focus on emerging markets such as China and India, and further strengthened the development of new products, especially medical treatment devices, and expanded its product line to the clinical treatment field. In the first half of 2016, Alma Lasers products have received 5 new EU CE certifications.
Fosun Pharmaceutical stated that in the second half of 2016, it will adhere to the development strategy of “endogenous growth, extensional expansion, and integrated development”, increase mergers and acquisitions and integration of outstanding domestic and foreign pharmaceutical companies, and strengthen innovation The construction of R&D system, manufacturing system and product marketing system actively promotes the implementation of industrial internationalization. At the same time, Fosun Pharma will seize the development opportunities of the medical service industry, strengthen investment and management capabilities in the medical service field, further strengthen core competitiveness, and continuously improve operating performance; at the same time, it will continue to actively expand domestic and foreign financing channels to ensure sustainability. Development creates good conditions.
preferential policies upongeneric drugs.
The transaction is subject to customary regulatoryapprovals. Further details of the transaction are not disclosed.
